Puricorp Holdings Announced Publication of a Peer-Reviewed Clinical Pilot Study in the Esteemed Journal of Addiction Research and Therapy
Orlando, Florida (PRWEB) November 09, 2013 -- Puricorp Holdings announced publication of a peer-reviewed clinical pilot study in the esteemed Journal of Addiction Research and Therapy. The published research article is titled: Significantly Reduced Alcohol Use Disorders Identification Test (AUDIT) Scores in Moderate to Heavy Drinkers: A Pilot Study. The review by noted industry professionals focused on the excellent outcomes of the study participants using Puricorp’s proprietary formulation marketed under the Declinol™ alcohol recovery product brand. Participants started the study classified in the “hazardous drinking” category of the AUDIT test, and were in the “normal drinking” category at the completion of the 30 day test.
Puricorp is the leading manufacturer of targeted nutraceutical tools for recovery professionals and is committed to continually researching, testing and verifying its cutting edge technology. All Puricorp products are manufactured in the USA in FDA registered, cGMP compliant manufacturing facilities.
Puricorp Holdings, LLC owns the Declinol, Puridone, Apiquel, and InaBrex brands and companies that produce natural supplement-based products for Alcohol, Rx Pain Med/Opiates, Food and Smoking recovery.
For further information or to see a copy of the peer reviewed publication, Practitioners and Healthcare Professionals involved in treatment of addictions, or individuals seeking qualified Practitioner/Addiction Counselor help may visit http://www.PuricorpHoldings.com or call 800-775-8851. For in-home private addiction treatment programs for those individuals who do not yet have a Practitioner support team, visit http://www.declinol.com or http://www.puridone.com.
Jonathan Kirven, Puricorp, http://www.puricorpholdings.com, +1 3212979099, [email protected]
Share this article